Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids.

Qilong Wang | Xiaoying Zhuang | Jingyao Mu | Zhong-Bin Deng | Hong Jiang | Lifeng Zhang | Xiaoyu Xiang | Baomei Wang | Jun Yan | Donald Miller | Huang-Ge Zhang
Nature communications | 2013

Although the use of nanotechnology for the delivery of a wide range of medical treatments has potential to reduce adverse effects associated with drug therapy, tissue-specific delivery remains challenging. Here we show that nanoparticles made of grapefruit-derived lipids, which we call grapefruit-derived nanovectors, can deliver chemotherapeutic agents, short interfering RNA, DNA expression vectors and proteins to different types of cells. We demonstrate the in vivo targeting specificity of grapefruit-derived nanovectors by co-delivering therapeutic agents with folic acid, which in turn leads to significantly increasing targeting efficiency to cells expressing folate receptors. The therapeutic potential of grapefruit-derived nanovectors was further demonstrated by enhancing the chemotherapeutic inhibition of tumour growth in two tumour animal models. Grapefruit-derived nanovectors are less toxic than nanoparticles made of synthetic lipids and, when injected intravenously into pregnant mice, do not pass the placental barrier, suggesting that they may be a useful tool for drug delivery.

Pubmed ID: 23695661

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCATS NIH HHS, United States
    Id: UH2 TR000875
  • Agency: NCI NIH HHS, United States
    Id: R01CA137037
  • Agency: NCI NIH HHS, United States
    Id: R01CA116092
  • Agency: NCI NIH HHS, United States
    Id: R01 CA107181
  • Agency: BLRD VA, United States
    Id: I01 BX000962
  • Agency: NCI NIH HHS, United States
    Id: R01 CA116092
  • Agency: NCI NIH HHS, United States
    Id: R01 CA137037
  • Agency: NCCIH NIH HHS, United States
    Id: R01AT004294
  • Agency: NCI NIH HHS, United States
    Id: R01CA107181
  • Agency: NCCIH NIH HHS, United States
    Id: R01 AT004294

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


A-549 (tool)

RRID:CVCL_0023

Cell line A-549 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

CT26 (tool)

RRID:CVCL_7254

Cell line CT26 is a Cancer cell line with a species of origin Mus musculus

View all literature mentions

BALB/cAnNCrl (tool)

RRID:MGI:2683685

laboratory mouse with name BALB/cAnNCrl from MGI.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions